Acute myeloid leukemia m2 low-risk, relative to high-risk is still relatively well-treated, and 70% to 80% cure rate can be obtained with chemotherapy alone. The treatment of acute myeloid leukemia partially differentiated (AML-M2) is determined by a combination of bone marrow cell morphology, chromosomal abnormalities or gene mutations, immunophenotyping, and self status. Low-risk patients generally do not require bone marrow transplantation, and are treated with 6 to 8 courses of chemotherapy, followed by outpatient follow-up, regular repeat bone marrow biopsies and refinement of other investigations to assess remission status, and dynamic monitoring of microscopic residual disease (MRD). Drugs include cytarabine and desmethoxazole. Acute myeloid leukemia m2 is low-risk and has a relatively good prognosis, but there is still a risk of relapse. Early diagnosis and early intervention should be made, and standardized treatment should be received under the guidance of physicians, with regular reviews to monitor relevant indicators, with a view to long-term survival.